Method of administering amantadine prior to a sleep period
Methods of nighttime administration of amantadine to reduce sleep disturbances in patient undergoing treatment with amantadine are described, as well as compositions of extended release amantadine that are suitable for nighttime administration.
1. A method of administering a dose of a pharmaceutical composition of a drug, wherein the drug is selected from the group consisting of amantadine and pharmaceutically acceptable salts thereof, to a human patient in need thereof, comprising administering said dose of said pharmaceutical composition to said human patient orally, once daily 0 to 4 hours before bedtime, wherein said dose of said pharmaceutical composition comprises: (i) 220 mg to 455 mg of the drug; and (ii) one or more excipients, wherein at least one of said one or more excipients modifies the release of said drug to provide an extended release dosage form,
wherein, a unit dosage form of said pharmaceutical composition has an in vitro dissolution profile characterized by release of said drug from said pharmaceutical composition that is not more than 25% in two hours and at least 80% at 12 hours using a USP Apparatus II (Paddles) at 50 rpm with 500 ml water at 37° C. as the dissolution medium, and
wherein when said pharmaceutical composition is dosed in a single dose, fasted, human pharmacokinetic study in healthy subjects, the Tmax for amantadine is 8 to 20 hours.
2. The method of claim 1 , wherein said Tmax is 9 to 18 hours.
3. The method of claim 1 , wherein said Tmax is 11 to 18 hours.
4. The method of claim 1 , wherein said in vitro dissolution profile is characterized by release of the drug from said pharmaceutical composition that is not more than 10% in one hour.
5. The method of claim 1 , wherein said in vitro dissolution profile is characterized by release of the drug from said pharmaceutical composition that is 40% to 80% in 6 hours.
6. The method of claim 4 , wherein said in vitro dissolution profile is characterized by release of the drug from said pharmaceutical composition that is 40% to 80% in 6 hours.
7. The method of claim 1 , wherein said in vitro dissolution profile is characterized by release of the drug from said pharmaceutical composition that is 25% to 55% in 6 hours.
8. The method of claim 4 , wherein said in vitro dissolution profile is characterized by release of the drug from said pharmaceutical composition that is 25% to 55% in 6 hours.
9. The method of claim 1 , wherein said in vitro dissolution profile is characterized by release of the drug from said pharmaceutical composition that is 30% to 50% in 4 hours.
10. The method of claim 4 , wherein said in vitro dissolution profile is characterized by release of the drug from said pharmaceutical composition that is 30% to 50% in 4 hours.
11. The method of claim 5 , wherein said in vitro dissolution profile is characterized by release of the drug from said pharmaceutical composition that is 30% to 50% in 4 hours.
12. The method of claim 1 , wherein said pharmaceutical composition comprises one, two, three or four unit dosage forms.
13. The method of claim 1 , wherein said pharmaceutical composition comprises one, two, or three capsules containing coated pellets.
14. The method of claim 1 , wherein said pharmaceutical composition comprises one, two, or three capsules.
15. The method of claim 1 , wherein said pharmaceutical composition is selected from the group consisting of one unit dosage form comprising 340 mg of said drug and two unit dosage forms each comprising 170 mg of said drug.
16. The method of claim 15 , wherein said drug is a pharmaceutically acceptable salt of amantadine.
17. The method of claim 15 , wherein said drug is amantadine hydrochloride.
18. The method of claim 1 , wherein said drug is a pharmaceutically acceptable salt of amantadine.
19. The method of claim 1 , wherein said drug is amantadine hydrochloride.